The Use of Factor IX Concentrates in Man: a 9-Year Experience of Scottish Concentrates in the South-East of Scotland

Abstract

During the last 9 yr, 2 factor IX concentrates produced in Scotland, PPSB and DEFIX, were used for the treatment of hemophilia B and acquired coagulation disorders, including those due to liver disease, coumarin therapy, neonatal immaturity and postoperative bleeding. During the period of study, 112 batches of DEFIX and 40 batches of PPSB were used in the Edinburgh and South-East Scotland Region. Data were analyzed from 575 non-hemophilic patients, receiving 968 treatment episodes, and 24 hemophiliacs. Serial coagulation studies and analysis of retrospective data showed that both concentrates corrected the coagulation deficiencies in all the patient groups. There was no evidence of intravascular coagulation due to concentrate infusion.